



TURNING NOVEL DISCOVERIES
INTO INNOVATIVE HEALTH CARE SOLUTIONS

KANE
BIOTECH

KANE BIOTECH INC.
CORPORATE PROFILE

KANE BIOTECH INC. CORPORATE PROFILE

Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse biofilms. Biofilms are a major cause of a number of serious medical problems including chronic infections and medical device related infections. They develop on surfaces such as catheters, prosthetic implants, teeth, lungs and the urogenital tract. Biofilms are pervasive, costly to deal with and approximately 80% of all human bacterial infections involve biofilms. The healing of chronic wounds alone costs the United States health care system \$20 Billion per year.

BIOFILMS ARE:

- Highly resistant to antibiotics and antimicrobials
- Cause hospital acquired infections
- Cause failure in chronic wound healing

KANE BIOTECH IS CURRENTLY DEVELOPING TWO LEAD TECHNOLOGY PLATFORMS:

- DispersinB™, a novel antibiofilm enzyme that inhibits as well as disperses microbial biofilms, with applications in wound care, medical devices, oral care and animal healthcare. Kane is currently developing a DispersinB™ based antibiofilm/antimicrobial wound gel for healing chronic wounds.
- PS/CHX, a broad-spectrum antimicrobial/antibiofilm composition comprising FDA-approved protamine sulfate and chlorhexidine, with applications in anti-infective medical device coatings, animal care and dairy and food processing industries. This technology has been licensed to Harland Medical Systems to develop antimicrobial urinary and venous access catheters.

VISION

To develop innovative products that prevent infectious diseases and have a positive impact on human health.

MISSION

We will contribute to the improvement of human health through our leadership in the research and development of innovative solutions that improve the standard of healthcare and contribute

to the solution of problems that cost over \$500 billion each year in equipment damage, energy loss and medical expenses. These solutions will be innovative products to prevent and disperse biofilms.

BUSINESS MODEL

Kane Biotech is a research and development company focused on the discovery and development of novel products to prevent and disperse bacterial biofilms. The objective of our business strategy is to create value for our shareholders by establishing partnerships for the optimal development and execution of our products.

DISCOVERY

- Internal discovery of novel technologies
- In-licensing of exclusive, novel biofilm targets

DEVELOPMENT

- Develop and test prototypes
- Conduct pre-clinical performance tests
- Examine durability, stability & biocompatibility
- Partnership research and development agreements

COMMERCIALIZATION

Partnerships and licensing agreements with leading companies to manufacture and commercialize

PRODUCT PIPELINE

Kane Biotech has one of the leading collections of biofilm related technologies, positioning the Company at the forefront of this rapidly developing and vastly underserved field. Kane's products are designed to make significant contributions to human health problems such as treating chronic wounds, preventing hospital-acquired medical device related infections and preventing tooth decay.

TECHNOLOGY PLATFORM	PRODUCT	DISCOVERY	PRE-CLINICAL	CLINICAL TRIAL	PARTNER	LAUNCH
PS/CHX	Urinary Catheter Coating	██████████	██████████	██████████	██████████	
	Urinary Catheter Coating	██████████	██████████	██████████	██████████	
	Veterinary Catheter Coating	██████████	██████████	██████████	██████████	
	New Business Development Expansion	██████████	██████████	██████████	██████████	
DISPERSINB™	Topical Wound Gel	██████████	██████████			
	Topical Wound Gel (+TRI)	██████████	██████████			
(+TRI)	Venous Catheter Coating	██████████	██████████			
(+TRI)	Urinary Catheter Coating	██████████	██████████			
CSP	Toothpaste & Mouthwash	██████████	██████████			

HIGHLIGHTS



DISPERSINB™

DispersinB™ has been the topic of numerous third party research studies and publications from such renowned research institutions as; the Department of Technology and Health in Italy, the Southwest Regional Wound Care Center in Lubbock, Texas, Harvard-MIT and Boston College in Cambridge, Massachusetts, the University of Medicine & Dentistry of New Jersey in New Brunswick, New Jersey and Baylor College of Medicine in Houston, Texas.

In May 2007, the FDA completed their review of Kane's request for designation for the Company's Triclosan-DispersinB™ Antimicrobial Wound Care Gel. They concluded that the gel is a combination product and have assigned the Center of Devices and Radiological Health as the lead agency for pre-market review and regulation based on the product's primary mode of action.

In March 2008 Kane signed an agreement with BioVectra, a pharmaceutical manufacturer, to manufacture clinical grade DispersinB™. The production of clinical grade DispersinB™ is an integral part of Kane's development plans to bring this technology to market.

Kane Biotech, with DispersinB™, was mentioned as one of only a handful of companies and products around the world which work towards preventing

biofilm formation and dispersing already formed biofilms in a June 2007 L.A. Times article.

DispersinB™ has shown great results preventing biofilm formation in recent studies.

PS/CHX

Kane Biotech has signed a commercial licence agreement with Harland Medical Systems to develop and commercialize Kane's PS/CHX antimicrobial technology for use in coating urinary, vascular and veterinary catheters. Prototypes of a coated urinary catheter are currently being developed to bring this product to the market.


PS/CHX was the focus of a recent research publication. The paper, entitled "Efficacy of Combination of Chlorhexidine and Protamine Sulphate against Device-Associated Pathogens" authored by Dr. Rabih Darouiche at Baylor College of Medicine, Houston, Texas, appeared in the Journal of Antimicrobial Chemotherapy. The study demonstrated that the combination of protamine

sulfate and chlorhexidine (PS/CHX) has a synergistic inhibitory effect on E. coli and synergistic antibiofilm activity against E. coli, Pseudomonas aeruginosa and Staphylococcus epidermidis.


Recent U.S. legislation, which comes in to effect October 2008, dictates that Medicare and Medicaid will no longer reimburse hospitals for hospital acquired infections,

such as urinary tract and blood stream infections caused by catheters. Furthermore, hospitals will not be permitted to charge patients for such infections, thus creating a need for hospitals to prevent these types of infections. This change in the market presents an even greater opportunity for a PS/CHX coated catheter.

E. Coli CsrA



PS/CHX has shown great results in preventing microbial growth in recent studies.



5-1250 Waverley Street
Winnipeg, Manitoba
R3T 6C6 Canada

PHONE: 204.453.1301
FAX: 204.453.1314
EMAIL: info@kanebiotech.com

kanebiotech.com



KANE
BIOTECH